Verastem Oncology completes rolling NDA submission to FDA for ovarian cancer treatment

Verastem Oncology ( NASDAQ: VSTM ) completed its rolling NDA to the U.S. FDA for combination of avutometinib and defactinib for adults with recurrent KRAS mutant low-grade serous ovarian cancer, who received at least one prior systemic therapy.

The company is currently enrolling patients with recurrent LGSOC regardless of KRAS mutation status for RAMP 301, an international Phase 3 trial. Source: Press Release More on Verastem Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity Seeking Alpha’s Quant Rating on Verastem Historical earnings data for Verastem Financial information for Verastem.